ATI-2138
Alopecia Areata
Key Facts
About Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies for immuno-inflammatory diseases with high unmet need. The company's core strength is its proprietary KINect® platform, which enables rapid discovery of selective kinase inhibitors. Having divested its commercial assets, Aclaris now focuses entirely on advancing a promising pipeline, including candidates for rheumatoid arthritis, alopecia areata, and atopic dermatitis, aiming to address critical 'white spaces' in treatment paradigms.
View full company profileAbout Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies for immuno-inflammatory diseases with high unmet need. The company's core strength is its proprietary KINect® platform, which enables rapid discovery of selective kinase inhibitors. Having divested its commercial assets, Aclaris now focuses entirely on advancing a promising pipeline, including candidates for rheumatoid arthritis, alopecia areata, and atopic dermatitis, aiming to address critical 'white spaces' in treatment paradigms.
View full company profileTherapeutic Areas
Other Alopecia Areata Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| Stem Cell Educator Therapy | Throne Biotechnologies | Phase 2 |
| RO-7239361 (BMS-986166) | Rohto Pharmaceutical | Phase 2 |
| Rezpegaldesleukin | Nektar Therapeutics | Phase 2b |
| Exploratory Asset | Veradermics | Discovery |
| Bempikibart (ADX-914) | Q32 Bio | Phase 2a |